Acquisition Announced
argenx SE acquisition of Forte Biosciences
US$2.2bn equity value
Announced 27 Jul 2026 · NASDAQ: FBRX · US$77.00 cash per share · 86% premium
Advisers
Forte Biosciences
Target
- Financial adviser
- Legal adviser
- Fairness opinion
argenx SE
Acquirer
- Financial adviser
- Legal adviser
- Information Agent
- Target
- Forte Biosciences
- Acquirer
- argenx SE
- Target based in
- United States
- Buyer based in
- Netherlands
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- UCB acquisition of Candid Therapeutics May 2026 · US$2.2bn · Biotech
- GSK acquisition of RAPT Therapeutics Jan 2026 · US$2.2bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of AtaiBeckley Jul 2026 · US$2.8bn · Biotech
Sources
- Jul 2026 Guggenheim Securities: Exclusive Financial Advisor to Forte Biosciences on its Sale to argenx guggenheimsecurities.com
- 27 Jul 2026 Tender offer communication (SC TO-C), Forte Biosciences, Inc. sec.gov
- 27 Jul 2026 Press release (EX-99.1, exhibit), argenx to Acquire Forte Biosciences, Inc., Adding sec.gov
- 27 Jul 2026 Freshfields Advises argenx on its $2.2bn Acquisition of Forte Biosciences freshfields.com
- 6 Aug 2026 Tender offer statement (SC TO-T), Forte Biosciences, Inc. sec.gov
- 6 Aug 2026 Target response to tender offer (SC 14D9), Forte Biosciences, Inc. sec.gov
